详情页

当前位置：首页 > 详情页

MATN1-AS1 Promotes Tumour Metastasis and Sunitinib Resistance via E2F2 in Clear Cell Renal Cell Carcinoma

97| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [2]Anhui Provincal Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui, China. [3]Department of Urology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. [4]Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

出处：

DOI：

ISSN：

关键词： ccRCC E2F2 EMT lncRNA MATN1-AS1 sunitinib resistance

摘要：

It has become increasingly recognised that MATN1-AS1 is involved in multiple tumour development. The role of MATN1-AS1 in clear cell renal cell carcinoma (ccRCC), however, is still largely unrecognised. This study investigated the molecular functions of MATN1-AS1 in promoting ccRCC metastasis and sunitinib resistance. MATN1-AS1 was found to be mainly located in the cytoplasm and was upregulated in ccRCC, and a positive association was seen between greater levels of MATN1-AS1 expression and worse clinical outcomes. Downregulating MATN1-AS1 significantly hindered cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT). MATN1-AS1 promoted tumour growth and metastasis in vivo. Mechanismly, MATN1-AS1 targeted microRNA miR-214-5p, thereby upregulating E2F2 and promoting E2F2-mediated EMT. We discovered that MATN1-AS1 also promoted sunitinib resistance via E2F2 in vitro. Collectively, our research uncovered the protumor characteristics of MATN1-AS1 and suggested it as a therapeutic target for reverse sunitinib resistance in ccRCC.© 2025 The Author(s). Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2026]版：

无

最新[2025]版：

大类 | 3 区医学

小类 | 3 区细胞生物学 3 区医学：研究与实验

JCR分区：

出版当年[2025]版：

无

最新[2024]版：

Q2 CELL BIOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 4.2 最新[2024版] 4.7 最新五年平均 0 出版当年[2025版] 0 出版当年五年平均 4.2 出版前一年[2024版]

第一作者：

第一作者机构： [1]Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [2]Anhui Provincal Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui, China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. [2]Anhui Provincal Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Anhui, China. [4]Department of Urology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]结直肠癌EMT相关LncRNA的研究进展 [2]Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC. [3]过表达及敲减lncrnarp11-521c20.3的非小细胞肺癌a549稳转细胞株的构建 [4]lncRNA及外泌体lncRNA在心血管疾病研究的进展 [5]17-AAG耐药性的产生促进结肠癌细胞发生EMT改变 [6]Polyphyllin Ⅲ regulates EMT of lung cancer cells through GSK-3β/β-catenin pathway [7]Cyclo-oxygenase-2 promotes migration and invasion of breast cancer MDA-MB-231 cells by regulating EMT [8]侵袭性垂体腺瘤中lncRNA-mRNA的共表达网络 [9]The Mechanism of TRIM21 Inhibiting the Invasion and Migration of ccRCC by Stabilizing ASS1 [10]NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC.